Expert Picks From EASL 2024

Ashwani K. Singal, MD, MS, highlights four abstracts from EASL Congress 2024.

OCTOBER 30, 2024

MASH Therapy Pipeline Growing, With a Mix of Results

After years without drug treatments for metabolic dysfunction–associated steatohepatitis, recently data have ...

AUGUST 22, 2024

ACG Issues Updated Guidance on Alcohol-Associated Liver Disease

The American College of Gastroenterology recently published a guideline on alcohol-associated liver disease.

AUGUST 14, 2024

Transitioning Patients From Pediatric to Adult Hepatology Care Requires a Team Approach

MASH is a growing concern in the pediatric population, meaning more patients than ever are transitioning from ...

APRIL 9, 2024

FDA Approves Resmetirom, First Drug for MASH

The FDA granted accelerated approval to the first medication for the treatment of MASH, resmetirom (Rezdiffra, ...

MARCH 15, 2024

Combination of Noninvasive Tests Identifies Later-Stage Fibrosis in MASH

A combination of noninvasive tests can identify patients with metabolic dysfunction–associated ...

DECEMBER 22, 2023

Pegozafermin Shows Promise for Treating MASH

The new drug pegozafermin could offer a promising treatment for patients with metabolic ...

DECEMBER 6, 2023

Societies Change Term for Fatty Liver To Focus on Steatosis

After years of discussion and review, an international working group has announced recently that they will refer to ...

AUGUST 28, 2023